GLP-1s and the Bigger Health Picture
For a long time, public conversation around GLP-1 medications has been dominated by one theme: weight loss. And while weight loss is certainly part of the picture for some people, it is becoming increasingly clear that this is far from the whole story.
A growing body of research suggests that GLP-1 receptor agonists may have important benefits that extend beyond body weight alone, with implications for cardiovascular health, kidney health, metabolic disease, and other obesity-related conditions. What is emerging is a far more complex and clinically significant picture than many early headlines suggested. At The Balance Project, we believe this is an area that deserves far more informed, nuanced conversation. Because when a class of medications becomes widely discussed in public life, but poorly understood in the wider health conversation, we risk reducing something medically important to a simplified cultural narrative. And right now, that narrative is still far too narrow.
What are GLP-1s?
GLP-1 receptor agonists are a class of medications originally developed to support blood glucose regulation in people with type 2 diabetes. More recently, they have become widely known for their role in weight management. But these medications do more than influence appetite. They act on pathways involved in glucose control, insulin secretion, gastric emptying, satiety, and broader metabolic regulation. As research has developed, scientists and clinicians have begun to understand that these effects may have meaningful consequences across multiple body systems. That matters, because obesity, insulin resistance, cardiovascular disease, inflammation, fatty liver disease, and metabolic dysfunction do not exist in isolation. They are deeply interconnected.
The evidence is expanding
A recent peer-reviewed review article published in the New England Journal of Medicine makes this shift in understanding especially clear. It notes that, beyond their well-established effects on blood glucose and body weight, large-scale randomised controlled trials have shown that GLP-1 receptor agonists can reduce cardiovascular risk and slow progression to renal failure in certain populations. That is a significant development. Because it means these medications are increasingly being viewed not only through the lens of weight or diabetes management, but through the broader lens of cardiometabolic health. This wider perspective is echoed in a recent review published in eClinicalMedicine, part of The Lancet family of journals. That paper describes the “expanding role” of GLP-1 receptor agonists and discusses evidence and emerging potential across areas including cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, sleep apnoea, and inflammatory mechanisms. Taken together, these publications point to an important shift: GLP-1s are increasingly being understood not simply as “weight-loss drugs,” but as therapies that may influence multiple aspects of metabolic and systemic health.
Why this matters
This matters because language shapes understanding. When GLP-1s are discussed only in terms of appearance, body size, or rapid weight loss, the conversation becomes reductive very quickly. It loses sight of the fact that these medicines were developed in response to real metabolic and clinical needs, and that their effects may be relevant to much more than the number on a scale. It also creates a problem for public understanding. Many people now recognise the names of these medications, but far fewer understand what they do, who they may be appropriate for, where the evidence is strongest, what the limitations are, and why clinicians are increasingly interested in their wider health effects. That gap between visibility and understanding is important. Because as interest grows, the quality of conversation around these medications needs to grow with it.
More nuance, less noise
This does not mean GLP-1s should be treated as a miracle solution, nor does it mean they are appropriate for everyone. Like all medications, they sit within a bigger clinical picture. Questions around side effects, long-term use, access, equity, discontinuation, medical oversight, and individual suitability all matter. So does the fact that some benefits are already well-supported by stronger evidence than others. But that is exactly the point. We need more nuance, not less. We need conversations that move beyond cultural reactions and into evidence-based understanding. We need to be able to hold two truths at once: that these medications have been over-simplified in public discourse, and that they also deserve careful, critical, medically grounded discussion. That kind of understanding is especially important in women’s health and midlife health conversations, where metabolic change, cardiovascular risk, insulin resistance, and body composition are often discussed in fragmented or overly superficial ways.
A broader shift in how we think about health
What is perhaps most interesting about the GLP-1 conversation is that it reflects a broader shift in medicine itself. Health is rarely one-dimensional. Metabolic health is not just about weight. Cardiovascular risk is not just about cholesterol. Hormonal health is not just about one symptom. And increasingly, medicine is recognising that therapeutic interventions may have wider system-level effects than first understood. GLP-1s are one example of that. They remind us that the body does not operate in neat, separate compartments. And they remind us, too, that our conversations about health need to evolve as the evidence evolves.
Why greater understanding is needed now
At The Balance Project, we feel strongly that greater understanding in this area is needed now. Not because everyone should be on these medications. Not because they are without complexity. And not because weight is no longer relevant. But because reducing GLP-1s to a weight-loss headline does not do justice to the science, the clinical context, or the people trying to make informed decisions about their health. This is an area that deserves better education, better language, and better public understanding. It deserves a conversation rooted in evidence rather than assumption. And it deserves the kind of nuance that allows people to ask smarter questions: What do these medications actually do? Where is the evidence strongest? Who may benefit beyond weight reduction alone? What do we still not know? And how do we talk about them in ways that are medically accurate, ethically responsible, and free from the usual noise that so often surrounds bodies and weight?
The bigger takeaway
The emerging evidence does not suggest that GLP-1s are simply “good for everything,” and it would be careless to frame them that way. What it does suggest is more interesting than that. It suggests that GLP-1 receptor agonists may play a broader role in health than previously appreciated, with clinically meaningful effects in specific areas beyond weight loss alone. And as the evidence base grows, so too must our understanding. At The Balance Project, we believe that better health conversations begin with better questions, clearer evidence, and a willingness to move beyond simplistic narratives. GLP-1s are not just a weight-loss story. And the sooner our conversation catches up with the science, the better.
Always with balance. Always with you.
